News

After five years, the probability of remaining free from treatment failure was 77.8% for patients who underwent superficial curettage.

Olpasiran significantly lowers oxidized phospholipids on apolipoprotein B but has no impact on systemic inflammatory markers in cardiovascular disease.

Researchers aimed to establish a plasma ctDNA sequencing assay and evaluate its effectiveness in assessing tumour genetics and treatment response.

A Phase III trial has shown that rezivertinib offers superior progression-free survival compared to gefitinib as a first-line treatment in EGFR-mutated locally advanced or metastatic non-small-cell lung cancer.

Study shows combined endobronchial ultrasound and endoscopic ultrasound (CUS) is a highly reliable tool for ruling out N2 disease in patients with PET-negative lung cancer.

A new self-healing E-Skin recovers within 10 seconds, enabling AI-assisted real-time health monitoring in extreme conditions.

A Phase III trial shows adding daratumumab to VRd enhances treatment response in transplant-ineligible multiple myeloma patients.

A recent study has uncovered a worrying link between diabetes and the rapid emergence of antibiotic resistance.